{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:41:42Z","timestamp":1760186502969,"version":"build-2065373602"},"reference-count":130,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.hoc.2012.12.003","type":"journal-article","created":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T05:20:19Z","timestamp":1364966419000},"page":"303-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy"],"prefix":"10.1016","volume":"27","author":[{"given":"Deborah M.","family":"Stephens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2012.12.003_bib1","unstructured":"Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), SEER stat fact sheet: chronic lymphocytic lymphoma. Based on November 2011 SEER data submission, posted to the SEER web site. 2012. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed June 1, 2012."},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2012.12.003_bib3","first-page":"14","article-title":"Monoclonal antibodies in cancer therapy","volume":"12","author":"Scott","year":"2012","journal-title":"Cancer Immun"},{"issue":"4","key":"10.1016\/j.hoc.2012.12.003_bib4","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.hoc.2012.12.003_bib5","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V83.5.1390.1390","article-title":"Retention of B-cell-specific monoclonal antibodies by human lymphoma cells","volume":"83","author":"Press","year":"1994","journal-title":"Blood"},{"issue":"43","key":"10.1016\/j.hoc.2012.12.003_bib6","doi-asserted-by":"crossref","first-page":"42427","DOI":"10.1074\/jbc.M308802200","article-title":"Store-operated cation entry mediated by CD20 in membrane rafts","volume":"278","author":"Li","year":"2003","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 expression and function","volume":"16","author":"Uchida","year":"2004","journal-title":"Int Immunol"},{"issue":"3","key":"10.1016\/j.hoc.2012.12.003_bib8","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2012.12.003_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1172\/JCI0216390","article-title":"Cholesterol, lipid rafts, and disease","volume":"110","author":"Simons","year":"2002","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.hoc.2012.12.003_bib10","first-page":"2143","article-title":"Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells","volume":"119","author":"Ivanov","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.hoc.2012.12.003_bib11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in\u00a0vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2012.12.003_bib12","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.176.4.2600","article-title":"The shaving reaction: rituximab\/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes","volume":"176","author":"Beum","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.hoc.2012.12.003_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in\u00a0vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.hoc.2012.12.003_bib14","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2003-07-2548","article-title":"Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia","volume":"103","author":"Farag","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib15","first-page":"43","article-title":"Dysregulated cytokine production by monocytes from chronic lymphocytic leukemia patients","volume":"13","author":"Anand","year":"1998","journal-title":"Cancer Biother Radiopharm"},{"issue":"8","key":"10.1016\/j.hoc.2012.12.003_bib16","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2012.12.003_bib17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.seminhematol.2010.01.005","article-title":"Rituximab in chronic lymphocytic leukemia","volume":"47","author":"Jaglowski","year":"2010","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.hoc.2012.12.003_bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J\u00a0Clin Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2012.12.003_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ijc.2910270310","article-title":"Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia","volume":"27","author":"Ziegler","year":"1981","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2012.12.003_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V63.2.305.305","article-title":"Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells","volume":"63","author":"Kay","year":"1984","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2012.12.003_bib21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2012.12.003_bib22","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2012.12.003_bib23","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2012.12.003_bib24","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2012.12.003_bib25","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2012.12.003_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","article-title":"Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy","volume":"24","author":"Byrd","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2012.12.003_bib29","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","article-title":"Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712","volume":"29","author":"Woyach","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2012.12.003_bib30","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/cncr.21535","article-title":"The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia","volume":"104","author":"Del Poeta","year":"2005","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2012.12.003_bib31","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2012.12.003_bib32","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2012.12.003_bib33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.23993","article-title":"Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia","volume":"115","author":"Tsimberidou","year":"2009","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.hoc.2012.12.003_bib34","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1182\/blood-2008-10-184853","article-title":"Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens","volume":"113","author":"Lin","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2012.12.003_bib35","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2012.12.003_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2012.12.003_bib37","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2012.12.003_bib38","first-page":"330","article-title":"Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG)","volume":"112","author":"Fischer","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9747","key":"10.1016\/j.hoc.2012.12.003_bib39","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.hoc.2012.12.003_bib40","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2012.12.003_bib41","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.hoc.2012.12.003_bib42","first-page":"980","article-title":"Final analysis of a phase 2 study of lenalidomide and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"10.1016\/j.hoc.2012.12.003_bib43","first-page":"291","article-title":"Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia (CLL) a multicenter study of the CLL research consortium","volume":"118","author":"James","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23144","article-title":"Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia","volume":"112","author":"Del Poeta","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2012.12.003_bib45","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V97.12.3995","article-title":"Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia","volume":"97","author":"Zecca","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2012.12.003_bib46","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood.V99.3.1092","article-title":"Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia","volume":"99","author":"Ghazal","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2012.12.003_bib47","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/sj.leu.2402676","article-title":"Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia","volume":"16","author":"Gupta","year":"2002","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2012.12.003_bib48","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.20665","article-title":"Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia","volume":"81","author":"D'Arena","year":"2006","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2012.12.003_bib49","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V100.6.2260","article-title":"Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia","volume":"100","author":"Hegde","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2012.12.003_bib50","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2012.12.003_bib51","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance","volume":"17","author":"Byrd","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM200101043440120","article-title":"Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab","volume":"344","author":"Dervite","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2012.12.003_bib53","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"10.1016\/j.hoc.2012.12.003_bib55","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib56","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX","volume":"183","author":"Pawluczkowycz","year":"2009","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.hoc.2012.12.003_bib57","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2012.12.003_bib58","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2012.12.003_bib59","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2012.12.003_bib60","first-page":"3912","article-title":"A\u00a0phase II trial of ofatumumab for\u00a0older patients and patients who refuse fludarabine-based regimens with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"118","author":"Flinn","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"24","key":"10.1016\/j.hoc.2012.12.003_bib61","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1182\/blood-2010-12-323980","article-title":"Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia","volume":"117","author":"Wierda","year":"2011","journal-title":"Blood"},{"issue":"15 Suppl","key":"10.1016\/j.hoc.2012.12.003_bib62","first-page":"6516","article-title":"Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)","volume":"30","author":"Falchi","year":"2012","journal-title":"J Clin Onc (ASCO Annual Meeting Abstracts)"},{"issue":"21","key":"10.1016\/j.hoc.2012.12.003_bib63","first-page":"3898","article-title":"Ofatumumab based chemoimmunotherapy (CIT) for patients with previously untreated CLL","volume":"118","author":"Shanafelt","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"10.1016\/j.hoc.2012.12.003_bib64","first-page":"4619","article-title":"Efficacy of ofatumumab and high-dose methylprednisolone for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL)","volume":"118","author":"Teichman","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"10.1016\/j.hoc.2012.12.003_bib65","first-page":"4615","article-title":"Ofatumumab and bendamustine in previously treated CLL and SLL","volume":"118","author":"Ujjani","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"15 Suppl","key":"10.1016\/j.hoc.2012.12.003_bib66","first-page":"6508","article-title":"A\u00a0phase Ib\/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases","volume":"30","author":"Jaglowski","year":"2012","journal-title":"J Clin Onc (ASCO Annual Meeting Abstracts)"},{"issue":"15 Suppl","key":"10.1016\/j.hoc.2012.12.003_bib67","first-page":"6518","article-title":"A\u00a0phase I\/II study of the selective phosphatidylinositol 3-kinase-delta (PI3K{delta}) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL)","volume":"30","author":"Furman","year":"2012","journal-title":"J Clin Onc (ASCO Annual Meeting Abstracts)"},{"issue":"8","key":"10.1016\/j.hoc.2012.12.003_bib68","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1074\/jbc.M510171200","article-title":"The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms","volume":"281","author":"Ferrara","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"17","key":"10.1016\/j.hoc.2012.12.003_bib69","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2012.12.003_bib70","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2174\/138955711795843374","article-title":"New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia","volume":"11","author":"Laurenti","year":"2011","journal-title":"Mini Rev Med Chem"},{"issue":"22","key":"10.1016\/j.hoc.2012.12.003_bib71","first-page":"3726","article-title":"Crystal structure analysis reveals that the novel type ii anti-CD20 antibody GA101 interacts with a similar epitope as rituximab and ocrelizumab but in a fundamentally different way","volume":"114","author":"Niederfellner","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"10.1016\/j.hoc.2012.12.003_bib72","first-page":"2379","article-title":"In\u00a0vitro activity of the Type II anti-CD20 antibody GA101 in refractory, genetic high-risk CLL","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"10.1016\/j.hoc.2012.12.003_bib73","first-page":"2365","article-title":"Depletion of chronic lymphocytic leukemia cells from whole blood samples mediated by the anti-CD20 antibodies rituximab and GA101","volume":"114","author":"Patz","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"10.1016\/j.hoc.2012.12.003_bib74","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib75","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1535-7163.MCT-10-0385","article-title":"Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101","volume":"10","author":"Dalle","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"10.1016\/j.hoc.2012.12.003_bib76","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","article-title":"Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients","volume":"119","author":"Salles","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2012.12.003_bib77","first-page":"884","article-title":"Phase I study of RO5072759 (GA101) in relapsed\/refractory chronic lymphocytic leukemia","volume":"114","author":"Morschhauser","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2 Suppl","key":"10.1016\/j.hoc.2012.12.003_bib78","first-page":"39","article-title":"Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed\/refractory chronic lymphocytic leukemia","volume":"96","author":"Cartron","year":"2011","journal-title":"Haematologica (EHA Annual Meeting Abstracts)"},{"issue":"22","key":"10.1016\/j.hoc.2012.12.003_bib79","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1182\/blood-2012-02-408773","article-title":"A\u00a0phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies","volume":"119","author":"Sehn","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2012.12.003_bib80","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2008-07-168146","article-title":"Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody","volume":"113","author":"Goldenberg","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2012.12.003_bib81","first-page":"3757","article-title":"Subcutaneous injections of low doses of humanized anti-cd20 veltuzumab for treatment of indolent B-cell malignancies","volume":"114","author":"Negrea","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"19","key":"10.1016\/j.hoc.2012.12.003_bib82","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1002\/cncr.24522","article-title":"A\u00a0phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia","volume":"115","author":"Jain","year":"2009","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2012.12.003_bib83","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2967\/jnumed.107.043489","article-title":"Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice","volume":"48","author":"Jacene","year":"2007","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib84","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","article-title":"New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies","volume":"25","author":"Robak","year":"2011","journal-title":"BioDrugs"},{"issue":"5","key":"10.1016\/j.hoc.2012.12.003_bib85","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.thj.6200119","article-title":"Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies","volume":"2","author":"Rossmann","year":"2001","journal-title":"Hematol J"},{"issue":"2","key":"10.1016\/j.hoc.2012.12.003_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in\u00a0vivo therapeutic responses to Campath-1H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.hoc.2012.12.003_bib87","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2249.1992.tb06421.x","article-title":"Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material","volume":"87","author":"Crowe","year":"1992","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.hoc.2012.12.003_bib88","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.4049\/jimmunol.134.5.3056","article-title":"Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes","volume":"134","author":"Hale","year":"1985","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2012.12.003_bib89","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.leu.2404014","article-title":"Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism","volume":"20","author":"Mone","year":"2006","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2012.12.003_bib90","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2012.12.003_bib91","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2012.12.003_bib92","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2012.12.003_bib93","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","article-title":"Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group","volume":"27","author":"Stilgenbauer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"10.1016\/j.hoc.2012.12.003_bib94","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2012.12.003_bib95","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission\u2014experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"18","author":"Wendtner","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2012.12.003_bib96","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","article-title":"Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia","volume":"98","author":"O'Brien","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2012.12.003_bib97","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/10428190903150839","article-title":"Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901","volume":"50","author":"Byrd","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"29","key":"10.1016\/j.hoc.2012.12.003_bib98","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2010.29.7978","article-title":"Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101","volume":"28","author":"Lin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2012.12.003_bib99","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/cncr.23271","article-title":"Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network","volume":"112","author":"Hainsworth","year":"2008","journal-title":"Cancer"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2012.12.003_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-5793(91)80988-F","article-title":"Novel structurally distinct family of leucocyte surface glycoproteins including CD9, CD37, CD53 and CD63","volume":"288","author":"Horejsi","year":"1991","journal-title":"FEBS Lett"},{"issue":"12","key":"10.1016\/j.hoc.2012.12.003_bib101","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/0167-5699(94)90222-4","article-title":"The ins and outs of the transmembrane 4 superfamily","volume":"15","author":"Wright","year":"1994","journal-title":"Immunol Today"},{"issue":"3","key":"10.1016\/j.hoc.2012.12.003_bib102","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4049\/jimmunol.140.3.905","article-title":"The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein","volume":"140","author":"Schwartz-Albiez","year":"1988","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.hoc.2012.12.003_bib103","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.4049\/jimmunol.172.5.2953","article-title":"A\u00a0regulatory role for CD37 in T cell proliferation","volume":"172","author":"van Spriel","year":"2004","journal-title":"J\u00a0Immunol"},{"issue":"7","key":"10.1016\/j.hoc.2012.12.003_bib104","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","article-title":"Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical","volume":"110","author":"Zhao","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2012.12.003_bib105","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","article-title":"Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals","volume":"21","author":"Lapalombella","year":"2012","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.hoc.2012.12.003_bib106","first-page":"56","article-title":"Phase 1 dose escalation study of TRU-016, an anti-CD37 SMIPTM protein in relapsed and refractory CLL","volume":"116","author":"Furman","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"10.1016\/j.hoc.2012.12.003_bib107","first-page":"1792","article-title":"Phase 1 study of Tru-016, an anti-CD37 SMIP\u2122 protein in naive and relapsed and\/or refractory CLL patients","volume":"118","author":"Awan","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"3","key":"10.1016\/j.hoc.2012.12.003_bib108","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/leu.2011.233","article-title":"Action of novel CD37 antibodies on chronic lymphocytic leukemia cells","volume":"26","author":"Krause","year":"2012","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.hoc.2012.12.003_bib109","first-page":"3726","article-title":"Potent B-cell depletion by IMGN529, a CD37-targeting antibody-maytansinoid conjugate for the treatment of B-Cell malignancies","volume":"118","author":"Deckert","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"18","key":"10.1016\/j.hoc.2012.12.003_bib110","doi-asserted-by":"crossref","first-page":"8331","DOI":"10.1158\/0008-5472.CAN-05-0095","article-title":"Preclinical antilymphoma activity of\u00a0a humanized anti-CD40 monoclonal antibody, SGN-40","volume":"65","author":"Law","year":"2005","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2012.12.003_bib111","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1182\/blood.V99.11.4087","article-title":"B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B\u00a0lymphocytes","volume":"99","author":"Damle","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2012.12.003_bib112","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","article-title":"A\u00a0crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation","volume":"196","author":"Clayton","year":"2002","journal-title":"J\u00a0Exp Med"},{"issue":"8","key":"10.1016\/j.hoc.2012.12.003_bib113","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.leu.2403398","article-title":"A\u00a0sustained activation of PI3K\/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B\u00a0cells","volume":"18","author":"Cuni","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2012.12.003_bib114","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.4049\/jimmunol.164.4.2200","article-title":"Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells","volume":"164","author":"Furman","year":"2000","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.hoc.2012.12.003_bib115","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood.V92.3.990","article-title":"Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells","volume":"92","author":"Romano","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2012.12.003_bib116","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1365-2141.2008.07548.x","article-title":"The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia","volume":"144","author":"Lapalombella","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2012.12.003_bib117","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3109\/10428190903440946","article-title":"A\u00a0phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia","volume":"51","author":"Furman","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"10.1016\/j.hoc.2012.12.003_bib118","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","article-title":"Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in\u00a0patients with chronic lymphocytic leukemia","volume":"26","author":"Andritsos","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2012.12.003_bib119","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2007-04-084756","article-title":"The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells","volume":"112","author":"Luqman","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2012.12.003_bib120","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3109\/10428194.2012.681655","article-title":"Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia","volume":"53","author":"Byrd","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"2\u20133","key":"10.1016\/j.hoc.2012.12.003_bib121","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1385\/IR:22:2-3:281","article-title":"CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification","volume":"22","author":"Fujimoto","year":"2000","journal-title":"Immunol Res"},{"issue":"19","key":"10.1016\/j.hoc.2012.12.003_bib122","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in\u00a0vitro and in\u00a0vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2012.12.003_bib123","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","article-title":"CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2012.12.003_bib124","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2008-10-182048","article-title":"The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates","volume":"113","author":"Zalevsky","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2012.12.003_bib125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00262-009-0746-z","article-title":"A\u00a0nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies","volume":"59","author":"Cardarelli","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"10.1016\/j.hoc.2012.12.003_bib126","first-page":"3425","article-title":"A\u00a0phase 1, open-label, multi-center, multiple-dose, dose-escalation study of MDX-1342 in patients with CD19-positive refractory\/relapsed chronic lymphocytic leukemia","volume":"114","author":"Camacho","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"25","key":"10.1016\/j.hoc.2012.12.003_bib127","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2009-06-228288","article-title":"Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways","volume":"115","author":"Stein","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2012.12.003_bib128","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/blood-2003-08-2836","article-title":"Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells","volume":"103","author":"Mone","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2012.12.003_bib129","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-04-017921","article-title":"Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab","volume":"108","author":"Stein","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2012.12.003_bib130","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3109\/10428190903186486","article-title":"A\u00a0phase I\/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia","volume":"50","author":"Lin","year":"2009","journal-title":"Leuk Lymphoma"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881200247X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881200247X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:59:20Z","timestamp":1760183960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985881200247X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":130,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S088985881200247X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2012.12.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2012.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}